Electra Therapeutics (ETRA) Financials: Revenue & Earnings
$190.70M
Market Cap
—
P/E
—
Forward P/E
—
Score
ETRA price $8.99 +0.47 +5.52%
ETRA fair value Not meaningful. Price $8.99.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| No data yet. | ||||
Yield —. Payout ratio —. Frequency —.
Safety score 34/100 · At risk. Payout ratio is not reported, so this part stays neutral. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. Yield is unknown, so this part stays neutral.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-21 | GORDON CARL L | Buy | 333.33K | $15.00 | 5.00M |
| 2026-09-21 | GORDON CARL L | Buy | 1.70M | — | — |
| 2026-09-21 | GORDON CARL L | Buy | 1.09M | — | — |
| 2026-09-21 | GORDON CARL L | Buy | 2.00M | — | — |
| 2026-09-21 | GORDON CARL L | Buy | 1.00M | $15.00 | 15.00M |
| 2026-09-21 | GORDON CARL L | Buy | 758.28K | — | — |
| 2026-09-21 | GORDON CARL L | Sell | 1.09M | — | — |
| 2026-09-21 | GORDON CARL L | Sell | 2.00M | — | — |
| 2026-09-21 | GORDON CARL L | Sell | 758.28K | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Buy | 333.33K | $15.00 | 5.00M |
| 2026-09-21 | ORBIMED ADVISORS LLC | Buy | 1.70M | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Buy | 1.09M | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Buy | 2.00M | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Buy | 1.00M | $15.00 | 15.00M |
| 2026-09-21 | ORBIMED ADVISORS LLC | Buy | 758.28K | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Sell | 1.09M | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Sell | 2.00M | — | — |
| 2026-09-21 | ORBIMED ADVISORS LLC | Sell | 758.28K | — | — |
| 2026-09-21 | Westlake BioPartners Fund I, L.P. | Other | 0 | — | — |
| 2026-09-21 | Westlake BioPartners Fund I, L.P. | Other | 0 | — | — |
| 2026-09-21 | Koe Gary S. | Buy | 63.66K | — | — |
| 2026-09-21 | Koe Gary S. | Sell | 63.66K | — | — |
| 2026-09-21 | Stagliano Nancy | Buy | 255.63K | — | — |
| 2026-09-21 | Stagliano Nancy | Sell | 255.63K | — | — |
| 2026-09-21 | Parry Graham | Buy | 85.50K | — | — |
| 2026-09-21 | Parry Graham | Sell | 85.50K | — | — |
| 2026-09-21 | Dong Quehuong (Kathy) | Buy | 455.48K | — | — |
| 2026-09-21 | Dong Quehuong (Kathy) | Sell | 455.48K | — | — |
| 2026-09-18 | ORBIMED ADVISORS LLC | Other | 2.00M | — | — |
| 2026-09-18 | ORBIMED ADVISORS LLC | Other | 1.09M | — | — |
| 2026-09-18 | ORBIMED ADVISORS LLC | Other | 758.28K | — | — |
| 2026-09-18 | ORBIMED ADVISORS LLC | Other | 1.70M | — | — |
| 2026-09-18 | Tucker David J. | Other | 114.00K | $4.96 | 565.44K |
| 2026-09-18 | Tucker David J. | Other | 73.40K | $15.00 | 1.10M |
| 2026-09-18 | Fust Matthew K | Other | 59.09K | $4.40 | 259.98K |
| 2026-09-18 | Fust Matthew K | Other | 77.71K | $4.96 | 385.46K |
| 2026-09-18 | Fust Matthew K | Other | 22.63K | $15.00 | 339.48K |
| 2026-09-18 | Dao Kim-Hien | Other | 62.63K | $4.40 | 275.58K |
| 2026-09-18 | Dao Kim-Hien | Other | 23.63K | $4.40 | 103.99K |
| 2026-09-18 | Dao Kim-Hien | Other | 103.99K | $5.05 | 525.16K |
| 2026-09-18 | Dao Kim-Hien | Other | 47.27K | $5.05 | 238.71K |
| 2026-09-18 | Dao Kim-Hien | Other | 309.68K | $4.96 | 1.54M |
| 2026-09-18 | Dao Kim-Hien | Other | 155.98K | $15.00 | 2.34M |
| 2026-09-18 | Parry Graham | Other | 101.15K | $4.40 | 445.05K |
| 2026-09-18 | Parry Graham | Other | 219.56K | $4.96 | 1.09M |
| 2026-09-18 | Parry Graham | Other | 155.98K | $15.00 | 2.34M |
| 2026-09-18 | Parry Graham | Other | 46.12K | $15.00 | 691.83K |
| 2026-09-18 | Parry Graham | Other | 4.19K | $15.00 | 62.90K |
| 2026-09-18 | Parry Graham | Other | 85.50K | — | — |
| 2026-09-18 | Parry Graham | Other | 114.00K | $4.96 | 565.44K |
| 2026-09-18 | Parry Graham | Other | 73.40K | $15.00 | 1.10M |
| 2026-09-18 | Koe Gary S. | Other | 35.45K | $5.23 | 185.41K |
| 2026-09-18 | Koe Gary S. | Other | 47.27K | $4.40 | 207.98K |
| 2026-09-18 | Koe Gary S. | Other | 18.91K | $5.05 | 95.48K |
| 2026-09-18 | Koe Gary S. | Other | 47.27K | $4.96 | 234.45K |
| 2026-09-18 | Koe Gary S. | Other | 231.94K | $4.96 | 1.15M |
| 2026-09-18 | Koe Gary S. | Other | 155.98K | $15.00 | 2.34M |
| 2026-09-18 | Koe Gary S. | Other | 11.80K | $15.00 | 177.00K |
| 2026-09-18 | Koe Gary S. | Other | 63.66K | — | — |
| 2026-09-18 | GORDON CARL L | Other | 2.00M | — | — |
| 2026-09-18 | GORDON CARL L | Other | 1.09M | — | — |
| 2026-09-18 | GORDON CARL L | Other | 758.28K | — | — |
| 2026-09-18 | GORDON CARL L | Other | 1.70M | — | — |
| 2026-09-18 | GORDON CARL L | Other | 22.63K | $15.00 | 339.48K |
| 2026-09-18 | Clark Christopher William | Other | 319.20K | $4.96 | 1.58M |
| 2026-09-18 | Clark Christopher William | Other | 292.78K | $15.00 | 4.39M |
| 2026-09-18 | Stagliano Nancy | Other | 94.54K | $5.23 | 494.43K |
| 2026-09-18 | Stagliano Nancy | Other | 288.81K | $4.96 | 1.43M |
| 2026-09-18 | Stagliano Nancy | Other | 68.82K | $15.00 | 1.03M |
| 2026-09-18 | Stagliano Nancy | Other | 255.63K | — | — |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 59.09K | $5.23 | 309.02K |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 281.99K | $4.40 | 1.24M |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 70.90K | $4.96 | 351.68K |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 759.20K | $4.96 | 3.77M |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 927.15K | $15.00 | 13.91M |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 167.80K | $15.00 | 2.52M |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 32.09K | $15.00 | 481.38K |
| 2026-09-18 | Dong Quehuong (Kathy) | Other | 455.48K | — | — |
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| No data yet. | ||||
Electra Therapeutics Inc. (ETRA) trades at $8.99, with a market cap of $190.70M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn
$190.70M
Market Cap
—
P/E
—
Forward P/E
—
Score